3D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockade-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

3D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockade

Published:2018 Issue:20 Volume:18 Page:3129-3143
ISSN:1473-0197
Container-title:Lab on a Chip
language:en
Short-container-title:Lab Chip

Author:

Aref Amir R.¹²³⁴,Campisi Marco¹²³⁴⁵^ORCID,Ivanova Elena¹²³⁴⁶,Portell Andrew¹²³⁴⁶,Larios Dalia¹²³⁴⁶,Piel Brandon P.¹²³⁴,Mathur Natasha¹²³⁴⁶,Zhou Chensheng¹²³⁴^ORCID,Coakley Raven Vlahos¹²³⁴,Bartels Alan¹²³⁴,Bowden Michaela¹²³⁴,Herbert Zach¹²³⁴,Hill Sarah¹²³⁴,Gilhooley Sean¹²³⁴,Carter Jacob¹²³⁴,Cañadas Israel¹²³⁴,Thai Tran C.¹²³⁴,Kitajima Shunsuke¹²³⁴,Chiono Valeria⁷⁸⁹¹⁰^ORCID,Paweletz Cloud P.¹²³⁴⁶,Barbie David A.¹²³⁴⁶,Kamm Roger D.⁵¹¹¹²⁴¹³^ORCID,Jenkins Russell W.¹²³⁴¹⁴^ORCID

Affiliation:

1. Department of Medical Oncology

2. Dana-Farber Cancer Institute

3. Boston

4. USA

5. Department of Mechanical Engineering

6. Belfer Center for Applied Cancer Science

7. Department of Mechanical and Aerospace Engineering

8. Politecnico di Torino

9. 10129 Turin

10. Italy

11. Massachusetts Institute of Technology

12. Cambridge

13. Department of Biological Engineering

14. Division of Medical Oncology

Abstract

Microfluidic culture has the potential to revolutionize cancer diagnosis and therapy.

Funder

National Cancer Institute

Massachusetts Institute of Technology

Politecnico di Torino

Compagnia di San Paolo

American Cancer Society

Publisher

Royal Society of Chemistry (RSC)

Subject

Biomedical Engineering,General Chemistry,Biochemistry,Bioengineering

Link

http://pubs.rsc.org/en/content/articlepdf/2018/LC/C8LC00322J

Reference56 articles.

1. The blockade of immune checkpoints in cancer immunotherapy

2. Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

3. Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers

4. Combination cancer immunotherapy and new immunomodulatory targets

5. Mechanisms of resistance to immune checkpoint inhibitors

Cited by 202 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cells in the 3D biomatrix on-chip: better mimicking the real micro-physiological system;Next Materials;2024-10

2. Cancer Patient-Derived Cell-Based Models: Applications and Challenges in Functional Precision Medicine;Life;2024-09-10

3. Microdissection tools to generate organoids for modeling the tumor immune microenvironment;Microsystems & Nanoengineering;2024-09-10

4. Targeting SRSF10 might inhibit M2 macrophage polarization and potentiate anti‐PD‐1 therapy in hepatocellular carcinoma;Cancer Communications;2024-09-02

5. Recapitulating the Cancer‐Immunity Cycle on a Chip;Advanced Healthcare Materials;2024-09-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3